Cumberland Pharmaceuticals Stock Fundamentals
| CPIX Stock | USD 1.39 0.04 2.80% |
Cumberland Pharmaceuticals fundamentals help investors to digest information that contributes to Cumberland Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cumberland Stock. The fundamental analysis module provides a way to measure Cumberland Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cumberland Pharmaceuticals stock.
At this time, Cumberland Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 701.3 K in 2024, whereas Selling General Administrative is likely to drop slightly above 8.9 M in 2024. Cumberland | Select Account or Indicator |
Cumberland Pharmaceuticals Company Operating Margin Analysis
Cumberland Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Cumberland Pharmaceuticals Operating Margin | (0.22) % |
Most of Cumberland Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cumberland Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Cumberland Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Cumberland Pharmaceuticals has an Operating Margin of -0.22%. This is 99.37% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The operating margin for all United States stocks is 96.01% lower than that of the firm.
Cumberland Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cumberland Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cumberland Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cumberland Pharmaceuticals competition to find correlations between indicators driving Cumberland Pharmaceuticals's intrinsic value. More Info.Cumberland Pharmaceuticals is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Cumberland Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cumberland Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Cumberland Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cumberland Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cumberland Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cumberland Pharmaceuticals by comparing valuation metrics of similar companies.Cumberland Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Cumberland Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cumberland Pharmaceuticals from analyzing Cumberland Pharmaceuticals' financial statements. These drivers represent accounts that assess Cumberland Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cumberland Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 79.3M | 44.7M | 69.6M | 25.6M | 29.4M | 28.0M | |
| Enterprise Value | 72.6M | 37.1M | 58.6M | 25.7M | 29.6M | 28.1M |
Cumberland Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.0479 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 22.52 M | ||||
| Shares Outstanding | 14.19 M | ||||
| Shares Owned By Insiders | 44.01 % | ||||
| Shares Owned By Institutions | 15.38 % | ||||
| Number Of Shares Shorted | 29.19 K | ||||
| Price To Earning | (16.05) X | ||||
| Price To Book | 0.78 X | ||||
| Price To Sales | 0.58 X | ||||
| Revenue | 39.55 M | ||||
| Gross Profit | 32.89 M | ||||
| EBITDA | (710.85 K) | ||||
| Net Income | (6.28 M) | ||||
| Cash And Equivalents | 18.22 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 18.43 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 1.80 X | ||||
| Book Value Per Share | 1.94 X | ||||
| Cash Flow From Operations | 6.09 M | ||||
| Short Ratio | 3.05 X | ||||
| Earnings Per Share | (0.59) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 91 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 19.73 M | ||||
| Total Asset | 81.78 M | ||||
| Retained Earnings | (17.49 M) | ||||
| Working Capital | 7.73 M | ||||
| Current Asset | 66.96 M | ||||
| Current Liabilities | 11.69 M | ||||
| Net Asset | 81.78 M |
About Cumberland Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cumberland Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cumberland Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cumberland Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 6.3 M | 6.6 M | |
| Total Revenue | 39.6 M | 39.8 M | |
| Cost Of Revenue | 11 M | 6.2 M | |
| Stock Based Compensation To Revenue | 0.01 | 0.02 | |
| Sales General And Administrative To Revenue | 0.27 | 0.18 | |
| Research And Ddevelopement To Revenue | 0.15 | 0.10 | |
| Capex To Revenue | (0.01) | (0.01) | |
| Revenue Per Share | 2.77 | 1.91 | |
| Ebit Per Revenue | (0.16) | (0.16) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| SGC | Superior Uniform Group | |
| VLN | Valens | |
| GNFT | Genfit |
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.